Results 91 to 100 of about 2,530 (165)

Brolucizumab: Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy

Clinical Ophthalmology, 2021
Julianna E Murray, Aaron S Gold, Azeema Latiff, Timothy G Murray Private Practice, Miami Ocular Oncology & Retina, Miami, FL, USACorrespondence: Timothy G MurrayMiami Ocular Oncology & Retina, 6705 Red Road Suite 412, Miami, FL, 33143, USAEmail tmurray ...
Murray JE, Gold AS, Latiff A, Murray TG
doaj  

High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab

Ophthalmology and Therapy
Introduction The aim of this study was to evaluate the efficacy and safety of escalating the dosage of intravitreal brolucizumab in patients with refractory neovascular age-related macular degeneration (AMD).
Jinsoo Kim, Min Seon Park, Bum-Joo Cho, Soonil Kwon   +3 more
doaj   +1 more source

Brolucizumab and immunogenicity [PDF]

Eye, 2020
Sharma, Ashish, Kumar, Nilesh, Parachuri, Nikulaa, Sharma, Rohini, Bandello, Francesco, Kuppermann, Baruch D., Loewenstein, Anat   +6 more
openaire   +5 more sources

Exploring current molecular targets in the treatment of neovascular age-related macular degeneration toward the perspective of long-term agents [PDF]

Long-lasting anti-vascular endothelial growth factor (anti-VEGF) agents have become an option to reduce treatment frequency, with ongoing research exploring optimal responses and safety profiles. This review delves into molecular targets, pharmacological
Abdolrahimzadeh, Barmak, Abdolrahimzadeh, Solmaz, Bassis, Lorena, Fragiotta, Serena, Marino, Alessandra, Sepe, Massimiliano   +5 more
core   +1 more source

Case series: Brolucizumab efficacy and safety in treating neovascular age‐related macular degeneration

MedComm – Future Medicine, Volume 4, Issue 1, March 2025.
Linling Cheng, Charlotte L. Zhang, Cheryl C. Lai, Ning Sun, Hiuwa Hang   +4 more
wiley   +1 more source

Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice [PDF]

, 2021
Eandi, C. M.
core   +1 more source

Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration:a systematic review [PDF]

Background: To systematically review the real-world outcomes of intravitreal faricimab treatment in patients with neovascular age-related macular degeneration (nAMD) to evaluate its efficacy and safety in clinical settings.
Grauslund, Jakob, Nasimi, Nasratullah, Nasimi, Safiullah, Subhi, Yousif, Vergmann, Anna Stage   +4 more
core   +1 more source

Occlusive retinal vasculitis associated with intravitreal Faricimab injections [PDF]

Purpose: We describe a case of occlusive vasculitis associated with intravitreal Faricimab (Vabysmo) injections. Methods: A retrospective case report.
De Silva, Samantha R., Fischer, M. Dominik, Hornby, Stella, Kiraly, Peter, Reichel, Felix F., Vemala, Roopa   +5 more
core   +2 more sources

Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration [PDF]

, 2023
doctoral ...
太田, 光
core  

Incidence of intraocular inflammation and its risk factors in patients treated with brolucizumab: a nationwide cohort study

Scientific Reports
This study aimed to evaluate the incidence of clinically significant intraocular inflammation (csIOI) after treatment with intravitreal injection (IVI) of brolucizumab and identify csIOI risk factors.
Hyo Song Park, Seung Won Lee, Hyunjin Park, Nang Kyeong Lee, Yong Joon Kim, Christopher Seungkyu Lee, Suk Ho Byeon, Sung Soo Kim   +7 more
doaj   +1 more source